Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Hot off the press.
Just published for American Society of Clinical Oncology (ASCO) Annual ASCO26 meeting.
- Pleased to share with the world our new paper in ASCO’s flagship journal – Journal Of Clinical Oncology
- ‘Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation’
- Led by the brilliant Jia Jenny Liu and Juliana Rodrigues Beal, Niamh Coleman, Benedikt Westphalen, Giuseppe Curigliano, Herbert Loong, MBBS FRCP FASCO
- Since the FDA’s landmark 2017 approval of pembrolizumab for MSI-H tumors,we have 9 tumor-agnostic drugs approved.
- <50% of eligible patients receive matched therapies. We mapped barriers across Europe | Asia-Pacific | Latin America | Africa | Middle East
We propose a 4-pillar framework:
- Biomarker testing infrastructure
- Innovative trial designs
- Harmonized regulatory and reimbursement pathways
- Genomically competent workforce precision medicine
Yes! Science is universal. Access shouldn’t depend on your geography.”
Title: Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation
Authors: Jia Liu, Juliana Beal, Niamh Coleman, Brigette B.Y. Ma, Herbert H. Loong, Hongyun Zhao, Lesley Seymour, Christoph Benedikt Westphalen, Giuseppe Curigliano and Vivek Subbiah
Other articles featuring Vivek Subbiah on OncoDaily.